GT 16239

Drug Profile

GT 16239

Latest Information Update: 03 Jan 2001

Price : $50

At a glance

  • Originator GelTex Pharmaceuticals
  • Class Antihyperlipidaemics
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 03 Jan 2001 Discontinued-Preclinical for Hypercholesterolaemia in USA (PO)
  • 21 Dec 2000 GelTex Pharmaceuticals has been acquired by Genzyme Corporation
  • 24 Feb 1999 Preclinical development for Hypercholesterolaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top